These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 8676802

  • 21. [Urinary albumin excretion in non-insulin-dependent diabetic patients. Effects of an angiotensin-converting enzyme inhibitor].
    Durruty P, Tapia JC, Ugarte C, Pérez E, Krause P, Soto N, García de los Ríos M.
    Rev Med Chil; 1996 Sep; 124(9):1036-44. PubMed ID: 9197016
    [Abstract] [Full Text] [Related]

  • 22. Angiotensin II inhibition attenuates postexercise proteinuria in rats.
    Gündüz F, Kuru O, Sentürk UK.
    Int J Sports Med; 2005 Nov; 26(9):710-3. PubMed ID: 16237614
    [Abstract] [Full Text] [Related]

  • 23. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
    Trimarchi H, Muryan A, Young P, Forrester M, Iotti A, Pereyra H, Lombi F, Seminario O, Alonso M, Iotti R.
    Medicina (B Aires); 2007 Nov; 67(5):445-50. PubMed ID: 18051227
    [Abstract] [Full Text] [Related]

  • 24. [Long-term effect of angiotensin-converting inhibitors in children with proteinuria].
    Camacho Díaz JA, Giménez Llort A, García García L, Jiménez González R.
    An Esp Pediatr; 2001 Sep; 55(3):219-24. PubMed ID: 11676896
    [Abstract] [Full Text] [Related]

  • 25. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
    Bazzi C, Rizza V, Paparella M, Casellato D, Napodano P, Olivieri G, D'Amico G.
    J Nephrol; 2009 Sep; 22(3):387-96. PubMed ID: 19557716
    [Abstract] [Full Text] [Related]

  • 26. Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.
    Nakhoul F, Khankin E, Yaccob A, Kawachi H, Karram T, Awaad H, Nakhoul N, Hoffman A, Abassi Z.
    Am J Physiol Renal Physiol; 2008 Mar; 294(3):F628-37. PubMed ID: 18094029
    [Abstract] [Full Text] [Related]

  • 27. Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors.
    Kohzuki M, Kanazawa M, Liu PF, Kamimoto M, Yoshida K, Saito T, Yasujima M, Sato T, Abe K.
    J Hypertens; 1995 Dec; 13(12 Pt 2):1785-90. PubMed ID: 8903652
    [Abstract] [Full Text] [Related]

  • 28. Proteinuria and albumin homeostasis in the nephrotic syndrome: effect of dietary protein intake.
    Rodrigo R, Bravo I, Pino M.
    Nutr Rev; 1996 Nov; 54(11 Pt 1):337-47. PubMed ID: 9110562
    [Abstract] [Full Text] [Related]

  • 29. Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease.
    Gansevoort RT, de Zeeuw D, de Jong PE.
    Nephrol Dial Transplant; 1995 Nov; 10(4):497-504. PubMed ID: 7623991
    [Abstract] [Full Text] [Related]

  • 30. Differing actions of dietary protein and enalapril on renal function and proteinuria.
    Hutchison FN, Martin VI, Jones H, Kaysen GA.
    Am J Physiol; 1990 Jan; 258(1 Pt 2):F126-32. PubMed ID: 2301589
    [Abstract] [Full Text] [Related]

  • 31. Enalapril and prednisone in children with nephrotic-range proteinuria.
    Delucchi A, Cano F, Rodriguez E, Wolff E, Gonzalez X, Cumsille MA.
    Pediatr Nephrol; 2000 Oct; 14(12):1088-91. PubMed ID: 11045392
    [Abstract] [Full Text] [Related]

  • 32. Nephropathy of cyanotic congenital heart disease: clinical characteristics and effectiveness of an angiotensin-converting enzyme inhibitor.
    Fujimoto Y, Matsushima M, Tsuzuki K, Okada M, Shibata M, Yanase Y, Usui K, Nagashima M.
    Clin Nephrol; 2002 Aug; 58(2):95-102. PubMed ID: 12227694
    [Abstract] [Full Text] [Related]

  • 33. Long-term therapy with enalapril in patients with nephrotic-range proteinuria.
    Proesmans W, Wambeke IV, Dyck MV.
    Pediatr Nephrol; 1996 Oct; 10(5):587-9. PubMed ID: 8897561
    [Abstract] [Full Text] [Related]

  • 34. Enalapril treatment of proteinuria in normotensive children.
    Sasinka MA, Podracka L, Boor A, Jurkovic I, Mitro A, Kovacs L.
    Bratisl Lek Listy; 1999 Sep; 100(9):476-80. PubMed ID: 10645036
    [Abstract] [Full Text] [Related]

  • 35. Adequate clinical control of congenital nephrotic syndrome by enalapril.
    Guez S, Giani M, Melzi ML, Antignac C, Assael BM.
    Pediatr Nephrol; 1998 Feb; 12(2):130-2. PubMed ID: 9543371
    [Abstract] [Full Text] [Related]

  • 36. The effect of angiotensin-converting enzyme inhibition and dietary protein restriction in the treatment of proteinuria.
    Don BR, Kaysen GA, Hutchison FN, Schambelan M.
    Am J Kidney Dis; 1991 Jan; 17(1):10-7. PubMed ID: 1986564
    [Abstract] [Full Text] [Related]

  • 37. Modulation of albuminuria by dietary protein and converting enzyme inhibition.
    Hutchinson FN, Schambelan M, Kaysen GA.
    Am J Physiol; 1987 Oct; 253(4 Pt 2):F719-25. PubMed ID: 2821830
    [Abstract] [Full Text] [Related]

  • 38. Nephrotic edema--pathogenesis and treatment.
    Palmer BF.
    Am J Med Sci; 1993 Jul; 306(1):53-67. PubMed ID: 8328511
    [Abstract] [Full Text] [Related]

  • 39. Albumin metabolism in the nephrotic syndrome: the effect of dietary protein intake.
    Kaysen GA.
    Am J Kidney Dis; 1988 Dec; 12(6):461-80. PubMed ID: 3057880
    [Abstract] [Full Text] [Related]

  • 40. Angiotensin converting enzyme inhibitors for reduction of proteinuria in children with steroid-resistant nephrotic syndrome.
    Milliner DS, Morgenstern BZ.
    Pediatr Nephrol; 1991 Sep; 5(5):587-90. PubMed ID: 1911144
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.